Quality of Life
In aNSCLC,
QoL in patients treated with Optune Lua was measured over 12 months1, 2
To measure QoL while using Optune Lua, patients were asked a broad range of questions from the EORTC Quality of Life survey across 5 functioning domains1,2
Optune Lua preserved patients' health-related quality of life compared with IOs or docetaxel1,3
Patients using Optune Lua + IOs or docetaxel reported stable scores vs IOs or docetaxel alone across predefined daily-functioning domains up to 1 year1,3,*
QoL at 12 Months
Adding Optune Lua to IOs or docetaxel did not impact global QoL1,3,*
See the pivotal study design
*Patient-reported data collected per EORTC QLQ-C30 at baseline and months 3, 6, 9, and 12. This 30-question survey covered 5 daily-functioning domains (Physical, Role, Social, Emotional, and Cognitive).3
aNSCLC, advanced non-small cell lung cancer; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; HRQoL, health-related quality of life; IO, immuno-oncology agent; QoL, quality of life.
References: 1. Optune Lua. Instructions for Use for non small cell lung cancer. Novocure; 2023. 2. Leal T, Kotecha R, Ramlau R, et al. Tumor treating fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. Supplementary appendix. Lancet Oncol. 2023;24(9):1002-1017. doi:10.1016/S1470-2045(23)00344-3 3. EORTC Quality of Life Group. EORTC QLQ-C30, Version 3.0. 1995. European Organisation for Research and Treatment of Cancer, Belgium. 4. Novocure Data on File 2023. EF-24/LUNAR clinical investigation report.